Kairos reports positive data for ENV-105 in mCRPC trial
Kairos Pharma reported that Phase 2 data showed ENV-105 plus apalutamide improved progression-free survival. The FDA filing documents a significant clinical advancement in metastatic prostate cancer therapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed